In this trial 70% of the 55 patients showed decrease in serum Prostate Specific Antigen (PSA) of greater than 50% for three weeks or longer. These efficacy results compare favourably with the pivotal TAX327 Taxotere registration trial, where 45% of patients had at least a 50% decrease in serum PSA level.